Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.64 |
| ▸ | BCR | P11274 | 5/20 | 0.61 |
| ▸ | LYN | P07948 | 4/20 | 0.59 |
| ▸ | ABL2 | P42684 | 3/20 | 0.59 |
| ▸ | CSK | P41240 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | FYN | P06241 | 2/20 | 0.59 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.59 |
| ▸ | BRAF | P15056 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.59 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.59 |
| ▸ | FRK | P42685 | 2/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.59 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.59 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.59 |
| ▸ | EPHA5 | P54756 | 2/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10266091 | 0.89 | ABL1 (0.68) | ABL1BCRLYNABL2CSK | |
| SCHEMBL9611043 | 0.88 | ABL1 (0.76) | ABL1BCRLYNABL2CSK | |
| SCHEMBL9610727 | 0.88 | ABL1 (0.76) | ABL1BCRLYNABL2CSK | |
| SCHEMBL9610953 | 0.88 | ABL1 (0.77) | ABL1BCRLYNABL2CSK | |
| SCHEMBL9610950 | 0.87 | ABL1 (0.75) | ABL1BCRLYNABL2CSK | |
| SCHEMBL9610999 | 0.87 | ABL1 (0.76) | ABL1BCRLYNABL2CSK | |
| SCHEMBL31734729 | 0.87 | ABL1 (0.80) | ABL1BCRLYNABL2CSK | |
| SCHEMBL588873 | 0.87 | ABL1 (0.80) | ABL1BCRLYNABL2CSK | |
| SCHEMBL12989932 | 0.87 | ABL1 (0.80) | ABL1BCRLYNABL2CSK | |
| SCHEMBL588874 | 0.87 | ABL1 (0.80) | ABL1BCRLYNABL2CSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012139027-A1 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135986-A1 | Bicyclic Heteroaryl Compounds | CYP3A43, CYP11B2, CYP2F1 | ABL1 110/4885BCR 250/4885LYN 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.